|
|
Ms. Shah earned a law degree from The George Washington University Law School in 2007, graduated with Merit Honors from London School of Economics with a Masters of Science in International Health Policy in 2000, and from Cornell University with a B.A. in Economics in 1998. Before entering law school, Ms. Shah worked for a contract research organization where she developed health economic models to determine the cost-effectiveness and cost-benefits of pharmaceutical products. In this role, she also managed and analyzed patient registries to determine patient reported outcomes, quality of life, and long-term costs of pharmaceutical products. Prior to that, Ms. Shah worked as an analyst for the European generic pharmaceutical trade association in Brussels. She is admitted to practice in the District of Columbia and Maryland.
Blog Posts
Allergan Settles with DOJ Related to the Sales and Marketing of BOTOX,
September 1, 2010
Misrepresentation of Active Ingredients Can Be Actionable Under the Lanham Act,
July 22, 2010
FDA to Increase Oversight of Home Use Medical Devices,
April 22, 2010
GAO Report Criticizes FDA's Oversight of GRAS Substances (Including Nanomaterials) and Points to Potential Legislative Fixes,
March 9, 2010
Proposed Rule Requires Sponsors to Report Suspected Falsification of Data to FDA,
February 19, 2010
|
